Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,754.94
(
0.65%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 181001

Thursday, 03/24/2016 8:13:09 AM

Thursday, March 24, 2016 8:13:09 AM

Post# of 257302
PTLA -28%/AH on Betrixaban failure in APEX study (as I predicted on numerous occasions):

http://finance.yahoo.com/news/portola-pharmaceuticals-announces-topline-results-110000380.html

PTLA’s contention that Betrixaban was “uniquely suited” to treat patients in this indication, where other FXa inhibitors had failed, never rang true, IMO.

Moreover, there was a pretty big red flag in the APEX trial design, as noted in #msg-105048954.

CC at 8:30am ET.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today